Author Topic: Ibudilast receives fast track designation--studied for SPMS and PPMS (MSAA Research News)  (Read 389 times)

0 Members and 3 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
AAN2018: Ibudilast slows brain atrophy in trial
« on: April 25, 2018, 03:59:20 pm »
From Multiple Sclerosis News Today (April 19), a brief report on a presentation at the AAN conference currently in session, "#AAN2018: Potential MS therapy ibudilast slows brain atrophy in trial":


https://multiplesclerosisnewstoday.com/2018/04/19/aan2018-ibudilast-slows-brain-atrophy-progressive-multiple-sclerosis-phase-2-trial/?utm_source=Multiple+Sclerosis&utm_campaign=e3d7ca8aab-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-e3d7ca8aab-71286581
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
1 Replies
211 Views
Last post November 14, 2018, 04:04:14 pm
by agate
0 Replies
60 Views
Last post February 02, 2019, 03:59:52 pm
by agate
0 Replies
60 Views
Last post March 21, 2019, 04:33:52 pm
by agate
0 Replies
63 Views
Last post April 04, 2019, 04:14:29 pm
by agate
0 Replies
14 Views
Last post April 18, 2023, 09:42:30 pm
by agate